•  

  • About Us

    InVenis Biotherapies is a biotech compagny, spin-off from academic laboratory U1172 and Taipei Medical University, developping innovative regenerative therapies based on blood platelet. Thanks to the high therapeutic potential of our product, we target the most severe diseases involving cell death, as the amyotrophic lateral sclerosis.

     

     

     

     

     

  • Therapeutic Concept

    Growth factors (GF) are natural molecules capable of stimulating cell growth, proliferation and differentiation. They are therefore ideal candidates to promote cell survival.The initial strategy of single growth factors failed by lack of efficacy. Stem cell transplantation is limited by the extensive alteration of the environnement. Their multiple GFs-rich secretome can be effective but is not maintained over time due to the rapid cell destruction. Platelets represent the powerful and natural healing system and contain an abundant source of physiological GFs mixtures, which has been shown in regenerative medicine of soft and hard tissue. Consequently, we develop a new biotherapy based on the human platelet lysates that can be continuously infused.

  • Applications

    Neurodegenerative diseases (NDD) such as Parkinson's disease (PD), Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS)... represent a major challenge for our society. They affect millions of patients and inexorably progress towards disability and death without treatment capable of slow this progression and bring catastrophic socio-economic consequences. All these diseases involve neuronal cell death. They are therefore a privileged target for our approach.
     
    Our First Target : Amyotrophic lateral sclerosis
     
    Amyotrophic lateral sclerosis is the most severe NDD, leading to death within 3 years. This disease is due to the death of motoneurone. It is a rare desease with an incidence of 120,000 cases worldwide corresponding to 328 new diagnoses every day. Currently available treatments extend survival by only 3 months. The impact is major for the patients but also for their family and the society with a cost estimated aroune 1,84 billions $ in Europe.
     

  • Technology

    From platelet concentrates that are not used in transfusion and are therefore condemned to destruction, Invenis Biotherapies applies its patented process to obtain a platelet lysate that is safer, more effective and compatible with the central nervous system (CNS).

    The platelet lysate will be delivered directly to the site of interest, so directly into the CNS for ALS

     

    The results of our research are extremely interesting with an effect on survival clearly superior to current treatments or the use of recombinant growth factors.

  • Team

    Matthieu Fisichella, PhD

    CEO & Co-founder

    Doctor-Engineer in Biology

    Challenge+, HEC

    Serial entrepreneur in life science, he previously co-created InBrain Pharma and Colmeris Medtech Previously, project manager in biology/health at SATT Nord (Lille), his mission was to detect and manage innovative projects.

    In 5 years, he detected more than 55 technologies, evaluated and set up 10 projects, obtained and managed more than 2 million euros of budget.

    Caroline Moreau, MD,PhD

    Clinical scientific advisor & Co-founder

    Professor in Neurology, University of Lille, Inserm, CHU of Lille.


    She counts 81 articles, participated in 17 clinical trials which included 10 multicentre studies including one European and 3 as coordinator.

    Assistant secretary of the SFN since 2016.

    French representative's at the EAN.

     

     

    Thierry Burnouf, PhD

    Blood product specialist & Co-founder

    Vice Dean, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan

     

    He has over 30 years of research and industrial experience in the manufacture of therapeutic human blood products and currently leads a research laboratory on new therapeutic applications of platelets in Taiwan.

    He serves as an Expert on blood product quality issues for several international organizations and societies.

    He has published more than 280 articles in international journals. He is also the inventor of 24 families of international patents relating to the manufacturing and viral inactivation processes of therapeutic blood products.

     

     

     

     

    David Devos, MD, PhD

    preclinical scientific advisor & Co-founder

    Professor of medical pharmacology, Neurologist at the university Lille, Inserm, University Hospital Center of Lille

     

    His main domain of research concerns development of innovative therapeutic strategies in neurodegenerative diseases from the concept through in vitro and in vivo research to large phase clinical trials.

    He participated in over 345 publications including 209 papers, conducted 30 clinical studies including 15 multi-centre trials, 14 as coordinator, 4 European Commission funded projects (H2020); career competitive research funding > 13M€

    He is consultant and running research at the expert center of Parkinson’s disease (PD) and Amyotrophic Lateral Sclerosis (ALS) of Lille. He is co-coordinating the French network of PD (NS-Park-F-CRIN) and of ALS (ACT4ALS-MND) and is involved for the research in Lille national referent Expert centers for PD and ALS with large cohorts of patients. He is coordinating the neurogenetic center of Lille .

    He obtained several awards: the European Pharmacology Prize, the French Medical Pharmacology Prize, the Health Professionals Competition prize Eurasanté University Foundation, I-SITE-ULNE, …

     

     

  • News

      InVenis Biotherapies, a Lille-based biotech start-up developing platelet lysate based...
    Tous Les Articles
    ×